Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 15, 2023

Long-Term Outcomes Following Neoadjuvant Ipilimumab Plus Nivolumab for Macroscopic Stage III Melanoma

Annals of Oncology

 

Additional Info

Annals of Oncology
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
Ann. Oncol 2023 Jan 18;[EPub Ahead of Print], JM Versluis, AM Menzies, K Sikorska, EA Rozeman, RPM Saw, WJ van Houdt, H Eriksson, WMC Klop, S Ch'ng, JV van Thienen, H Mallo, M Gonzalez, A Torres Acosta, LG Grijpink-Ongering, A van der Wal, A Bruining, BA van de Wiel, RA Scolyer, JBAG Haanen, TN Schumacher, ACJ van Akkooi, GV Long, CU Blank

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading